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The first clinical trial of oral methoxsalen as a
potential prophylactic against skin cancer in
susceptible humans was started in El Paso, Texas,
in June 1957, and is reported in this same issue
(1). It had been brought out in epidemiological
surveys based on a functioning cancer registry in
this area that skin cancers are more prevalent on
exposed areas of the head, neck and hands among
light skinned people in high, dry and sunny cli-
mates than elsewhere (2). Experimental studies
had established that psoralen may afford some
secondary protection of the skin against solar
injury (3, 4, 5). An unusual opportunity for early
resolution of the psoralen prophylaxis question
arose when Dr. John C. Belisario of Sydney,
Australia, volunteered to conduct a replicate of
the El Paso trial in his large population of skin
cancer patients, who are as numerous in Sydney
as in El Paso. An identical protocol was drawn up
providing for admission into the study of sus-
ceptible patients with a history of at least 1 docu-
mented skin cancer. Those selected had to be
willing to take an experimental drug and be
followed systematically at 3 months intervals
for up to 3 years. After entry into the study the
patients were given medication in individually
numbered plain bottles which had been coded,
numbered and labelled at the statistical control
center. The medication was 20 mg of oral, enteric
coated S-methoxypsoralen (methoxsalen) or an
identical appearing inert pill, randomly allocated
by the statistical unit. A sequential trial design
(6) was used as a rule for stopping the trial at the
earliest time that it should become possible to
detect either slightly harmful or moderately bene-
ficial effects of the drug as compared with the inert
control.
The first patient was started on the trial in
October, 1958, and the trial was discontinued in
September, 1960, in accord with the pre-arranged
stopping rule, after 92 patients had been entered.
RESULTS
The stopping rule lcd to the verdict of no im-
portant difference between drug #83 and drug
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#84 (Figure I). The results are summarized in
Table I. It is evident that the 2 treatments have
very similar effects on the occurrence of new
lesions. No significant differences were observed
in end effects, though an intermediate effect,
increased tanningJ, was observed in patients on
drug #84. Decoding, after the data analysis was
completed, revealed that drug #83 was the
inert control pill and drug #84 was 20 mg of
oral methoxsalen daily.
DISCUSSION
Increased tanning was observed in 31 out of
46 (67 per cent) of the psoralen patients as com-
pared with 15 out of 46 (32 per cent) for the con-
trols. This difference is statistically significant
(X02 = 9.7, p = 0.005). Since the drug is known
(3, 4, 5) to be active in potentiating sunburn and
tanning, this significant difference is taken to
signify patient adherence and an effective dose.
The hypothesis (7) that increased tanning in-
duced by the active drug would inhibit the
occurrence of skin cancer lesions was not sup-
ported by the trial. If there is a prophylactic
effect it must therefore be quite small, or delayed
beyond the 2 years follow-up period of this trial.
The number of new lesions observed at each 3
months examination is shown in Table II. Nearly
60 per cent of the quarterly re-examinations
revealed no new lesions in either control or
methoxsalen patients. About 20 per cent revealed
1 or 2 new lesions, and 10 per cent had 5 or more.
The number of patients having no new lesions,
and the proportions thereof, are given in Table
III. If the guiding hypothesis were true, a trend
of increasing proportions without new lesions
should have been observed, but was not.
The numbers of new lesions observed at each
successive re-examination is shown in Table IV.
Again, the psoralcn-control differences are not
significant, except at the 15 months comparison(X = 7.12, p = 0.01 in favor of pSoralcn
¶ Clinician's appraisal, confirmed by reflectance
meter readings and color photographs taken at
each visit.
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TABLE I
Summary of results
Drug
S83
DrugS84 Toa
Patients entered into
study 46 46 92
Outdoor occupation 28 27 55
Indoor occupation 18 19 37
Dropped out of study 14 16 30
Number of 3-months
examinations 136 131 267
Number of patients with
new lesions 80 77 157
Number of new lesions
observed 195 173 368
Cumulative probability of
first new lesions
At 3 months 0.39 0.49 0.44
At 6 months 0.68 0.57 0.63
At 9 months 0.76 0.63 0.70
Increased sunburn observed. 1 4 5
Increased tanning observed.. 15 31 46
Less sunburn observed 3 6 9
protection). This difference, however, was due
entirely to a single extreme patient on the control
regimen (83) who had 12 new lesions at this
examination. This same patient had 0, 0, 4, and
0 new lesions at 3, 6, 9, and 12 months. Hence the
difference at 15 months is taken with considerable
reservation, particularly since there was also an
extreme patient on psoralen who had 6, 10, 0,
and 15 new lesions at 3, 6, 9, and 12 months. The
number of patients having any new lesions (Table
III) is clearly not different under the 2 treat-
ments. We conclude, therefore, that there was no
difference between the rates of incidence of new
lesions under the 2 treatments, and that there was
no time trend in the incidence.
The initial distribution of age, sex, number of
previous lesions, and history of occupational
exposure to sunlight of the entire series at time of
entry into the study is shown in Table V. Chi-
square tests failed to find any significant associa-
tion of lesion susceptibility (number of previous
lesions) with exposure history, sex, or age.
In the randomized allocation of patients to
drug and control treatment no effort was made
to randomize within the various age, sex, lesion
history and exposure history subclasses that
might be thought of as initial conditioning
TABLE II
Number of new lesions observed upon re-
examination
Plot of Sequential Stopping Rule Based on
Comparative Incidence of New Lesions After 3,
6, and 9 Months of Treatment.
New Lesions Found
None
2
3
4
5 or more
Number of Examinations
TABLE III
Per Cent of Re-exami-
nations
Deug #83 Drug #84
59 59
11 12
10 8
7 7
3 7
10 7
136 131
Number of patients with no new lesions
Patients
Examined
Patients Per Cent
With No With No
New Lesions New LesionsExamination
Period
3 months
6 months
9 months
12 months
15 months
Total
Deug DrugS83 #84
41 41
31 32
29 26
22 22
13 10
136 131
Drug
583
25
14
19
15
7
80
Drug
S84
21
19
18
13
6
77
Drug Drug
#83 #84
61 51
45 59
66 65
68 59
54 60
59 59
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variables. The randomization nevertheless did
result in fairly equal distribution of these initial
variables in the 2 treatment series, as can be
seen in Table VI. We are thus assured of initial
comparability of the patient material in the 2
series.
Patient dropouts ran about one third, equally
frequent in control and psoralen patients. The
reasons are shown in Table VII. Nausea, a
common placebo response (8), occurred equally
with psoralen and the inert pill. Increased sun-
burn sensitivity accounted for 3 of the psoralen
dropouts, none of the controls. Two patients in
each series were found to have pre-existing health
conditions (e.g. gastric ulcer) that made con-
tinuation in a blind trial of a potent drug seem
inadvisable. No reason is known for the other 10
and 9 dropouts, who simply did not return. They
TABLE J\T
Number and incidence rates of new lesions
Incidence
New Lesions
per Patient
Drug Drug
s83 *84
1.51 1.61
1.74 1.41
1.00 0.62
1.23 1.86
1.77 0.50
1.43 1.32
probably represent failure of screening procedures
to select stable, cooperative patients into the
study.
BI0c5IEMIcAL IMPLIcATT0N5
The many conflicting reports on the relation-
ship of 8-methoxypsoralen and skin cancer may
be due to opposing effects of the drug itself as
well as to effects of compounds from the drug in
the body. In other words, the drug and its
metabolites or breakdown products may have
both carcinogenic and carcinostatic effects.
Psoralen absorbs ultraviolet light in the range of
the so-called carcinogenic wavelengths (9, 10).
These appear to center around 265 mu, an
absorption maximum of desoxyribonucleic acid
(DNA) (ba). Longer wavelengths up to and
around 300 mu. are fairly effective, as are shorter
wavelengths (i.e. to the vicinity of 250 mu)
but the longer ones are able to penetrate the skin
better. Mice irradiated with "short" ultraviolet
light (mostly under 280 mu) were reported to
have a somewhat lower incidence of skin tumors
when fed 8-methoxypsoralen in the diet (11). In
another study the differences between control and
psoralen-fed mice were found to be not significant
(9), possibly because of operation of opposing
effects, which will be discussed shortly.
The ultraviolet light energy which is absorbed
by the psoralen or its metabolites may be dissi-
pated partly as heat and partly as fluorescent
light. The drug itself (8-methoxypsoralen)
absorbs light at around 280 mu (a "carcino-
genic" wavelength) and fluoresces at 360 mu (9).
TABLE V
Initial distribution of patients by aye, sex, number of previous lesions, and solar exposure history
A eg
Outdoor Orrupations Indoor Orrupations Total
6 or More
Lesions
Less than 6
Lesions
6 or More
Lesions
Less than 6
Lesions
Total Total Male Female Total
Male Female Male Female Male Female Male Female
20—29 1 — 1 — 2 — — — — — 2 — 2
30—39 5 1 2 1 9 — 2 1 — 3 8 4 12
40—49 4 2 2 — 8 1 4 — 2 7 7 8 15
50—59 6 1 3 — 10 2 1 1 1 5 12 3 15
60—69 9 2 2 1 14 2 6 1 2 11 14 11 25
70—79 6 2 2 1 11 1 3 3 4 11 12 10 22
80—89 1 — — — 1 — — — — — 1 — 1
Total 32 8 12 3 55 6 16 6 9 37 56 36 92
Eaamination
Period
3 months
6 months
9 months
12 months
15 months
Total
New Lesions
Drug Drug$83 *84
62 66
54 45
29 16
27 41
23 5
Patients
Examined
Drug Drug
*83 *84
41 41
31 32
29 26
22 22
13 10
136 131195 173
222 THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
Initial Age
20—29
30—39
40—49
50—59
60—69
70—79
80—89
Total
Sex
Male
Female
Total
Lesion Status
Many (6 or more)
Few (less than 6)
Total
Exposure History
Outdoor occupation
Indoor occupation
Total
fOund to be very strongly mutagenic (12, 13).
Furthermore, the administration of 8-methoxy-
psoralen to mice irradiated with long wave]ength
ultraviolet light (mostly above 300 mu) is
associated with an increased incidence of skin
cancers. The mechanisms for this effect may be
related to the formation of free radicals after
absorption of 360 mu radiation, as proposed by
Pathak (14). The free radicals may catalyze
various biochemical reactions, including those
involved m producing erythema (15) and tumors
(16).
It is evident that much work remains to be done
in the elucidation of these multiform effects
before extensive clinical use of the psoralens can
be contemplated.
SUMMARY
1. In Sydney, Australia a replicate was run of
the El Paso, Texas, U.S.A. double-blind rando-
mized clinical trial of the effectiveness of oral
27 psoralen (8-methoxypsoralen) as a prophylactic
19 against skin cancer. The subjects were 92 men and
women who had demonstrated skin cancer
46 susceptibility by having already had at least 1
histologically verified lesion.
2. Psoralen was administered at the rate of
20 mg daily by mouth, taken in the morning.
46 Patients were presumed to be exposed frequently
to natural sunlight. Patients were seen every 3
months for systematic inventory of new lesions.
3. Side effects were minimal. Dropouts were
equally frequent in controls and psoralen patients.
4. Effective dose level and patient adherence
were confirmed by observation of the expected
primary effect, increased sunburn and tanning in
the psoralen patients.
5. It is concluded, as in the El Paso trial, that
methoxsalen in humanly tolerable tanning doses
has no immediate effect on the induction of new
skin cancer lesions. It cannot be said from this
trial whether larger doses or treatment over a
longer period than 15 months might be effective.
6. The biochemistry of 8-methoxypsoralen is
seen to imply the possibility of both carcinogenic
and carcinostatic action. More basic research is
required for understanding of conditions under
which the one or the other effect might take
precedence.
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